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Abstract: In age-related macular degeneration (AMD), both systemic and local zinc levels decline.
Elevation of zinc in clinical studies delayed the progression to end-stage AMD. However, the molecular
pathways underpinning this beneficial effect are not yet identified. In this study, we used differentiated
primary human fetal retinal pigment epithelium (RPE) cultures and long-term zinc supplementation
to carry out a combined transcriptome, proteome and secretome analysis from three genetically
different human donors. After combining significant differences, we identified the complex molecular
networks using Database for Annotation, Visualization and Integrated Discovery (DAVID) and
Ingenuity Pathway Analysis (IPA). The cell cultures from the three donors showed extensive
pigmentation, development of microvilli and basal infoldings and responded to zinc supplementation
with an increase in transepithelial electrical resistance (TEER) (apical supplementation: 443.2 ± 79.3%,
basal supplementation: 424.9 ± 116.8%, compared to control: 317.5 ± 98.2%). Significant changes were
observed in the expression of 1044 genes, 151 cellular proteins and 124 secreted proteins. Gene set
enrichment analysis revealed changes in specific molecular pathways related to cell adhesion/polarity,
extracellular matrix organization, protein processing/transport, and oxidative stress response by zinc
and identified a key upstream regulator effect similar to that of TGFB1.
Keywords: zinc; retinal pigment epithelium; age-related macular degeneration; transcriptome;
proteome; secretome; gene set enrichment; TGFB1
1. Introduction
Age-related macular degeneration (AMD) is a progressive, multi-factorial disease that leads to
irreversible vision loss [1–4]. It has no cure, and only limited treatment options are available to delay,
rather than prevent, the progression to end-stage AMD. Dietary intake of zinc has shown promise in
delaying the progression of AMD [5–7].
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Zinc is an essential micronutrient, critical for normal cellular processes in all organisms [8]. It acts
as a catalyst for more than 300 enzymes, and thousands of proteins require zinc for their normal
structure and function [9–21]. The eye has an unusually high content of zinc, primarily in the retinal
pigment epithelium (RPE) [21,22]. The RPE forms a monolayer of highly specialized pigmented cells
located between the neurosensory retina and the choroidal vasculature and plays a pivotal role in
the visual cycle and maintaining the health of the outer retina [23]. Consequently, extensive research
efforts have focused on the cell biology of the RPE [24–35] including studies examining the effects
of zinc supplementation [36–38]. These studies resulted in mixed outcomes [12,39–43] likely due to
the availability of zinc to exert biological function being affected by differing compositions of culture
media [44]. Recently, we established the optimal conditions to study the effects of zinc on human RPE
cells [38] and in this paper, we set out to identify the key regulatory pathways involved in long-term
zinc supplementation by combining the zinc-induced changes in cell transcriptome and proteome and
apical and basal secretomes. In this study, we identified specific regulatory pathways that might be
involved in mediating the positive effects of long-term zinc supplementation in AMD.
2. Materials and Methods
2.1. Retinal Pigment Epithelial (RPE) Cell Culture
Primary human fetal RPE cells (ScienCell, Carlsbad, CA, USA) from three donors with unknown
clinical or genetic background were used for our experiments at passage number three (P3). Cells were
seeded onto Corning 6-well transwell inserts (10 µm thick polyester inserts with 0.4 µm pore size,
4*106/cm2 pore density, Corning, Wiesbaden, Germany) in epithelial cell medium (EpiCM, ScienCell,
Carlsbad, CA, USA). After seven days, the cell culture medium was replaced with Miller medium with
1% FBS [45,46] for an additional four weeks in the absence or presence of 125 µM externally added
zinc (as zinc sulphate; Thermo Fisher Scientific, Waltham, MA, USA), resulting in ~10 nM bio-available
or free zinc [38,44]. Cellular differentiation was monitored through the development of cobblestone
morphology and increase in pigmentation using light microscopy and the increase in transepithelial
electrical resistance (TEER) was measured by using the EVOM2 Epithelial Voltohmmeter and STX2
electrodes (World Precision Instruments, Sarasota, FL, USA). The obtained results were analyzed using
two-way ANOVA and Tukey’s test and a p-value < 0.05 was considered significant.
At the end of the experiments, cells were washed with PBS (Thermo Fisher Scientific, Waltham,
MA, USA) 3 times for 2 min. Then differentiation media were replaced with serum-free Minimum
Essential Medium Eagle Alpha Modifications (Merck, Darmstadt, Germany). After 24 h, apical and
basal media (approximately 600 and 900 µl, respectively) were collected, snap frozen in liquid nitrogen
and stored at −80 ◦C until proteomics analysis was conducted. The transwell membranes containing
the cells were excised and divided into five equal-sized wedges. These were either immediately snap
frozen and kept at −80 ◦C or fixed for 15 min in 4% PFE (Merck, Darmstadt, Germany) diluted in
PBS (Thermo Fisher Scientific, Waltham, MA, USA) or kept in Karnovsky fixative (Agar, Essex, UK)
comprising 3% (v/v) glutaraldehyde, 1% (v/v) paraformaldehyde in 0.08 M sodium cacodylate buffered
to pH 7.4 with 0.1M HCl.
2.1.1. Immunofluorescence
For immunofluorescence analysis, the cells on the transwell membrane were permeabilized in
0.5% Triton-X (Merck, Darmstadt, Germany) in PBS for 10 min at 4 ◦C and then washed in 0.1%
Tween20 in PBS (PBST) (Merck, Darmstadt, Germany) and blocked with PBST with 5% goat sera
(Merck, Darmstadt, Germany) for one hour at room temperature. Next, samples were incubated with
primary antibodies PMEL17 (Agilent, Santa Clara, CA, USA, dilution 1:25), ZO-1 (BD Biosciences,
San Jose, CA, USA, 1:200), BEST-1 (Merck, Darmstadt, Germany, 1:50), and RPE65 (Merck Millipore,
Darmstadt, Germany, 1:50) diluted in PBST containing 1% goat sera. Following washing with PBST,
the samples were incubated with secondary antibodies in 1:200 in PBST with 1% goat sera for one hour
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in the dark at room temperature. After, the secondary antibody incubation samples were washed
with PBST for 5 min, followed by 5 min washing with PBS. Cell nuclei were then labelled for 15 min
with DAPI (Thermo Fisher Scientific, Waltham, MA, USA) diluted 1:1,000 in PBS. Finally, the samples
were washed for 5 min in PBS, before mounting onto Menzel-Glaser slides (Thermo Fisher Scientific,
Waltham, MA, USA) in Vectashield (Vector Laboratories, Burlingame, CA, USA). The flat mounts
were sealed by applying nail polish around coverslips. For negative control, the primary antibody
labelling was replaced by incubation with PBST only. Results were visualized using a Leica SP8
confocal microscope (Leica, Wetzlar, Germany) with a 40x/1.25 oil immersion objective. Images were
obtained and analyzed with Leica Application Suite X Image software (Leica, Wetzlar, Germany).
2.1.2. Transmission Electron Microscopy
For transmission electron microscopy, the 1% glutaraldehyde (Agar, Essex, UK) and 2.5%
paraformaldehyde-fixed samples were post-fixed in 1% (w/v) osmium tetroxide (Agar, Essex, UK) in
0.1 M PBS for 50 min, dehydrated and embedded in Araldite (Agar, Essex, UK). Semi-thin sections
were generated using Leica ultra-microtome (Leica, Wetzlar, Germany), stained with 1% (w/v) uranyl
acetate and Reynolds’ lead citrate and viewed with a JEOL JEM-1010 electron microscope (JEOL USA,
Peabody, MA, USA) and a Gatan Orius CCD camera (Gatan, Pleasanton, CA, USA).
2.2. Genotyping
For genotyping, genomic DNA was extracted from snap-frozen transwell inserts using AllPrep
DNA/RNA/Protein Mini Kit (Qiagen) following manufacturers’ instructions. The EYE-RISK genotyping
assay [47] was used to genotype 87 single-nucleotide polymorphisms (SNPs), including the 52
independently AMD-associated SNPs identified by the International AMD Genomics Consortium [2],
SNPs previously associated with AMD [48], and several candidate SNPs. For nine of the 52
AMD-associated SNPs, an alternative SNP in high linkage disequilibrium (≥0.80) was used.
Furthermore, the coding and splice-site regions of thirteen genes (C3, C9, CFH, CFI, TIMP3,
SLC16A8, ARMS2, CD46, CFB, HTRA1, ABCA4, CTNNA1, and PRPH2) were completely sequenced.
The targeted regions were enriched by single-molecule molecular inversion probes (smMIPs) followed
by next-generation sequencing of the library pools, as described previously [47].
A genetic risk score (GRS) for the 52 AMD-associated SNPs [2] was calculated based on the formula
GRS =
∑52
i=1(Gi βi), as described previously [47]: G1 represents the genotype of variant i, where
genotypes were coded as 0, 1 or 2 based on the number of minor alleles (0 = carrier of 0 minor alleles,
1 = carrier of one minor allele, 2 = carrier of two minor alleles). β1 represents the effect size of variant i
(natural logarithm of the fully conditioned odds ratio [OR] of the minor allele of variant i), based on
the genome-wide association study (GWAS) of the International Age-related Macular Degeneration
Genomics Consortium (IAMDGC) [2].
2.3. Multi-Omics Approach Development
2.3.1. Transcriptomics
For transcriptomic analysis, total RNA was extracted simultaneously with genomic DNA isolation
from snap-frozen transwell inserts using a AllPrep DNA/RNA/Protein Mini Kit (Qiagen) following
manufacturers’ instructions. The quality of RNA was analyzed using the AATI Fragment Analyzer and
Qubit (Thermo Fisher). Libraries were prepared by the QUB Genomics Core technology Unit using
the KAPA HyperPrep kit. Libraries were quantified, normalized and pooled in equimolar amounts
and sequenced on the Illumina NextSeq 5000. QC was performed with Qualimap following alignment
to human genome build GRCh37 (hg19). Raw counts calculated using htseq were analyzed further for
differentially expressed genes (DEG) performing quasi-likelihood F-test in edgeR package [49]. To filter
out lowly expressed genes, the following script was used: > keep <- rowSums(cpm(y)> 0.05) >= 1. To
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be considered as DEG, the Benjamini–Hochberg-adjusted P-value was less than 0.05. The full list and
raw data are deposited in the GEO database with dataset identifier GSE156452.
2.3.2. Proteomic Sample Preparation
For proteomic analysis, all solvents and water were purchased from Merck (Darmstadt, Germany)
as HPLC-grade purity. All chemicals were purchased from Sigma Aldrich (Taufkirchen, Germany)
unless stated otherwise. HPLC columns were obtained from Thermo Fisher Scientific (Dreieich,
Germany).
To analyze the secretomes of the RPE transwell cell culture, apical and basal supernatants were
thawed on ice and concentrated to approximately 100 µL volume by evaporation. To generate
sample fractions for optional metabolomic and lipidomic analyses, in addition to proteomics
the SIMPLEX extraction method was applied according to the protocol described elsewhere [50].
Finally, the methanol-containing phase was removed, and the protein pellet was air dried and frozen
at −80 ◦C until further analysis.
For cellular proteomic analysis, 200 µL of cold lysis buffer (Tris-buffered saline containing 1%
NP-40 and 2% cOmpleteTM protease inhibitor cocktail (Merck, Darmstadt, Germany/Roche, Basel,
Switzerland)) were added to one snap-frozen wedge of each transwell chamber, and the cells were
detached on ice using a cell pestle (Merck, Darmstadt, Germany, # Z359947-100EA). The resulting
suspension was vortexed and subsequently centrifuged at 16,000 × g at 4 ◦C for 10 min. The clear
supernatant was recovered, and the protein concentration was determined using a conventional assay
(Bradford, Biorad, California, USA). For each sample, a volume containing 10 mg of total protein was
used to perform a methanol/chloroform precipitation. The resulting protein pellet was air dried and
used for proteome analysis as described in the following section.
2.3.3. Proteome Analysis by Mass Spectrometry
Frozen protein pellets were recovered in 30 µL of 50 mM ammonium bicarbonate solution plus
an additional 4 µL of RapiGest SF Surfactant (Waters, Eschborn, Germany). Proteins were reduced
by adding dithiothreitol followed by an incubation with iodacetamide to alkylate cysteine residues.
Finally, limited proteolysis was performed by adding 1 µL of 0.5 µg/µL trypsin (Merck, Darmstadt,
Germany) and incubation at 37 ◦C for 12 h. The reaction was stopped by adding trifluoroacetic acid to
a final concentration of 5%. After centrifugation, the supernatants were processed using StageTips
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. LC–MS/MS
analysis was performed on a NanoRSLC3000 HPLC system (Dionex, Thermo Fisher Scientific, Waltham,
MA, USA) coupled to an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, Waltham, MA,
USA) by a nano spray ion source. Tryptic peptide mixtures were trapped on a nano trap column (75 µm
i.d. × 2 cm, packed with Acclaim PepMap100 C18, 3 µm, 100 Å; Dionex, Thermo Fisher Scientific,
Waltham, MA, USA), and separated on an analytical column (75 µm i.d. × 25 cm, Acclaim PepMap
RSLC C18, 2 µm, 100 Å; Dionex, Thermo Fisher Scientific, Waltham, MA, USA) applying a gradient of
actetonitrile in water with 0.1% formic acid.
For quantitative analysis, MS raw data were processed using the MaxQuant software
(version 1.5.3.30) [51]. Two missed cleavages per peptide were allowed. The peptide and protein
false discovery rates were set to 1%. The initial mass tolerance for precursor ions was set to 4.5 ppm
and the first search option was enabled with 20 ppm precursor mass tolerance. The fragment ion
mass tolerance was set to 0.5 Da. The SwissProt_2014 database (selected for homo sapiens, 20203
entries) was used for peptide and protein identification. The MaxQuant software-generated output
file “proteingroups.txt” was utilized for Pearson correlation, clustering and statistical analysis using
Perseus software version 1.5.5.3. All data were filtered for potential contaminants, peptides only
identified by side or reverse sequence. The dataset was filtered further on Log2 transformed LFQ values
to the minimum number of valid values “in at least one in total”, and missing values were imputed
using normal distribution in “separately for each column” mode. All numeric values were expressed
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as the mean ± standard deviation (SD) for the respective groups. Benjamini–Hochberg corrections of
significance B calculated by the Perseus software package were used to identify the intensity-dependent
significant outliers relative to a certain populations [51]. The adjusted p-value of less than 0.05
was considered a significantly enriched protein. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE [52] partner repository with the dataset
identifier PXD020860.
2.3.4. Functional Classification Pathway and Network Analysis
Gene ontology (GO) analysis, canonical pathway and network identification were performed
using Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics
Resources 6.8 with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [53,54], with
p-values of less than 0.05 considered as significant enrichment. In addition, we used the Ingenuity
Pathway Analysis (IPA 7.4, April 2009) with the HumanCyc database, with the default threshold
of IPA, a cut-off p-value of -log (p-value) < 1.3 used for statistically significant enrichment for top
canonical pathways. For overlapping canonical pathway visualization, the network was filtered for 250
significant pathways (p-value < 0.05) with a minimum of three common shared molecules. A total of
67 entries exported from relevant GWAS studies [2,55,56] were used in IPA for overlaying the dataset
on AMD-relevant molecules.
3. Results
3.1. Characterization of Human Primary RPE Cell Culture
Based on previous experiments [34,38], we used conditions under which RPE cells in
culture developed dense microvilli (Supplementary Figure S1A), basal infoldings (Supplementary
Figure S1A–C), extensive pigmentation that is localized to the apical aspects of the cells (Supplementary
Figure S1A,B) with pigment particles appearing in the microvilli (Supplementary Figure S1C), basal
lamina (Supplementary Figure S1D–E; red arrowheads) and expressed RPE-specific proteins such as
PMEL17, ZO-1, BEST-1 and RPE65 (Supplementary Figure S1G−J, respectively). In addition, sub-RPE
deposits are visible (Supplementary Figure S1D–F) similar to those of mature RPE in vivo [57,58].
While the cells from the three individuals all showed similar phenotypes (see Supplementary
Figure S1), there were differences between the cultured cells. Specifically, there were differences in their
pigmentation pattern (Figure 1A (donor (D)1-3)), the numbers of visible sub-RPE deposits (Figure 1A
(D1-3, labelled by red arrowheads) and the maximal TEER values reached after 5 weeks in culture
(Figure 1B (D1: 477.9 ± 28.4, D2: 244.4 ± 45 and D3: 1114.6 ± 27 Ohm × cm2)).
The genotypes of the 52 AMD-associated SNPs and rare variants in 13 genes identified in the three
donors are provided in Supplementary Table S1 (genotypes different between donors are highlighted
in bold). The donors had a relatively low genetic risk score (GRS) based on the 52 AMD-associated
SNPs: donor 1 has a GRS of −0.33; donor 2 has a GRS of −2.36; and donor 3 has a GRS of 0.95 compared
to the GRS of AMD patients [47]. The donors carried different genotypes for the major CFH SNP
rs10922109 (donor 1 CA, donor 2 AA, donor 3 CC), and carried the same low-risk genotype for the major
ARMS2 SNP rs10490924 (all three donors GG). In addition, donor 3 carries a rare, heterozygous variant
in the CFI gene (c.299C > T; p.Phe100Ser) of unknown clinical significance (Supplementary Table S1,
genotypes different between donors are highlighted in bold).
3.2. Zinc and RPE Barrier Function
Despite their differences, the cell cultures responded to zinc supplementation similarly with
respect to changes in transepithelial electrical resistance (TEER) values (Figure 1C), irrespective of
whether zinc was added apically or basally. Due to the differences in the maximum TEER values
(Figure 1B), the zinc-induced changes in barrier function were normalized to TEER values measured at
day 4 (Figure 1C). After this normalization, we found that either apical or basal zinc led to a significant
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increase in the TEER values from day 16 and this increase remained significant for the remainder of
the experiment (at week 4; control: increase of 317.5 ± 98.2%, zinc basal: increase of 424.9 ± 116.8%,
zinc apical: increase of 443.2 ± 79.3% relative to day 4).
Figure 1. Differences in characteristics between cultures from three donors. There were differences
between the three batches of cells in their pigmentation (A) and maximal transepithelial electrical
resistance (TEER) (B); each point is an average +/-SEM from triplicate measurements from each of
three donors.). Apical and basal zinc supplementation for 4 weeks significantly increased TEER values
(C); the samples from the three donors represent replicates, plotted as values normalised to 100% at
day 4; control (•), zinc apical supplementation (), and zinc basal supplementation (N). Scale bar
represents 100 µm. Experimental workflow for downstream analysis (D). * represents p-value < 0.05,
two-way ANOVA.
3.3. Multi-Omics Approach for the Effects of Zinc on RPE
After establishing that the cell cultures from the three donors share many phenotypic features
characteristic of differentiated RPE and responded similarly to zinc treatment in terms of TEER
measurement, we harvested samples for our multi-omics analysis as depicted in Figure 1D at the end
of week 5 in culture.
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3.3.1. Cellular Transcriptome
To perform transcriptomic analysis, RNA was isolated at the end of the week 5 culturing period
from the triplicate experiments. Using RNAseq, we were able to identify over 32,000 transcripts. A total
of 826 of these were significantly changed in the three independent samples after apical and 216 after
basal zinc supplementation when compared to untreated controls (Figure 2A, B, adjusted p-value < 0.05).
Apical zinc supplementation upregulated 415 and downregulated 411 transcripts (Figure 2A red and
blue dots, respectively). Basal zinc supplementation upregulated 157 and downregulated 59 transcripts
(Figure 2B). A total of 163 transcripts changed similarly after both apical and basal treatment (for
the full list of significantly changed transcripts see Supplementary Table S2).
Figure 2. Changes in transcriptome and proteome following zinc supplementation. Comparison of
cellular gene expressional after apical (A), or basal (B) zinc supplementation compared to untreated
controls. Red dots represent significantly upregulated while blue dot represents significantly
downregulated genes (adjusted p-value <0.05). Blue line indicates log2 fold change: 1 and -1.
Analysis of the cellular proteome following apical (C) or basal (D) zinc supplementation. When changes
in secreted proteins were analysed we found significant changes in both the apical (E,F) and basal (G,H)
secretomes following apical (E,G) or basal (F,H) supplementation with zinc. In C–H, open black circles
represent no change while red dots show significant significance B changes (adjusted p-value < 0.05).
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3.3.2. Cellular Proteome
In parallel to RNA isolation, we also isolated the protein fraction from the cells. We were able to
identify 2164 proteins in the RPE cells. Following apical zinc supplementation, significant changes
were observed in 89 (adjusted p-value < 0.05, Figure 2C, Supplementary Table S3). Basal application
of zinc resulted in significant changes in 62 proteins (adjusted p-value < 0.05, Figure 2D, red dots,
Supplementary Table S3). A total of 45 proteins changed similarly after both treatments.
There was an overlap in the mRNAs and proteins altered following apical supplementation of zinc
(CSRP1: 1.29 and 2.52, CRIP2: 0.76 and 1.78, TTR: -0.65 and 2.6 log2 fold change at the transcriptomic
and proteomic levels, respectively, Supplementary Tables S2 and S3). After basal zinc supplementation,
only CSRP1 was significantly changed in both transcriptome and proteome (CSRP1: 1.1 and 2.52 log2
fold change, at the transcriptomic and proteomic levels, respectively, Supplementary Tables S2 and S3).
3.3.3. Apical and Basal Secretomes
As many proteins changed following zinc supplementation could have been secreted from cells,
we collected apical and basal media for the analysis of protein secretion. We identified 1132 proteins in
the apical secretomes, of which 33 changed significantly to apical and 37 to basal zinc supplementation
(Figure 2E,F respectively, adjusted p-value < 0.05). In the basal secretome, we identified 839 proteins
from which 34 responded to apical (Figure 2G) and 20 to basal supplementation (Figure 2H, adjusted
p-value < 0.05). Twenty-one proteins changed similarly in the apical secretome and 9 in their basal
secretome after the treatments. The lists of proteins are provided in Supplementary Table S4.
Examining the overlaps between the changes in cellular transcriptome and apical secretome
after apical zinc supplementation, we found two overlaps: STC2 (0.35 and 3.53 log2 fold change at
the transcriptomic and apical secretome levels, respectively) and TPM1 (0.47 and −2.04 log2 fold change
at the transcriptomic and apical secretome levels, respectively). There were two overlaps between
cellular proteome and apical secretome: PSMA3 (2.04 and −3.05 log2 fold change at the proteomic and
apical secretome levels, respectively) and COL12A1 (1.59 and −2.61 log2 fold change at the proteomic
and apical secretome levels, respectively) (Supplementary Tables S2–S4).
Examining the overlaps between the cellular transcriptome and apical secretome after basal zinc
supplementation, we found one overlap: STC2 (5.56 and 3.84 log2 fold change at the transcriptomic
and apical secretome levels, respectively). There were two overlaps between cellular proteome and
apical secretome: RTN4 (1.51 and −4.2 log2 fold change at the proteomic and apical secretome levels,
respectively) and SERPINB12 (2.58 and 2.3 log2 fold change at the proteomic and apical secretome
levels, respectively) (Supplementary Tables S2–S4).
Examining the overlaps between cellular transcriptome and, this time, basal secretome after
apical zinc supplementation, we found two overlaps: MYL6 (0.37 and 2.65 log2 fold change at
the transcriptomic and basal secretome levels, respectively) and SELENBP1 (−0.47 and −3.7 log2 fold
change at the transcriptomic and basal secretome levels, respectively). There were three overlaps
between the cellular proteome and the basal secretome: ARG1 (2.36 and 3.18 log2 fold change at
the proteomic and basal secretome levels, respectively), DBI (−2.02 and 2.9 log2 fold change at
the proteomic and basal secretome levels, respectively) and SERPINB12 (3.6 and −4.34 log2 fold change
at the proteomic and basal secretome levels, respectively) (Supplementary Tables S2–S4).
When zinc was supplemented basally, there were no overlaps between the significantly changed
cellular transcriptome and secreted proteins. When the cellular proteome and the basal secretomes
were compared, the only significant change was observed in ARG1 (3.05 and 3.8 log2 fold change for,
respectively, Supplementary Tables S2–S4).
3.4. Pathway Identification
To evaluate the complex impact of zinc supplementation on RPE cells, we combined the significant
changes in transcriptome, intracellular proteome and the basal and apical secretomes following
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either basal or apical zinc supplementation and analyzed the data by DAVID and IPA. We converted
the protein symbols to gene symbols for the analysis, which resulted in 983 entries for apical and 335
entries for basal zinc treatment.
3.4.1. DAVID Gene Ontology (GO) and KEGG Pathway Analysis
The gene lists were first input into DAVID to identify biological processes, the involvement of
cellular components, molecular functions and KEGG pathways that were significantly affected by zinc
supplementation (the full list of the potential biological impacts is in Supplementary Table S5). Table 1
shows the top five most significant hits following zinc supplementation (p-value < 0.05).
3.4.2. IPA Canonical Pathways and Regulatory Effect Networks
Following the analysis in DAVID, we set out to identify the canonical pathways, upstream
regulators, disease associations and networks underpinning the effects of zinc supplementation by
entering the data in IPA that potentially increases the statistical power of our pathway analysis by
using an additional background database (summary of the analysis is in Supplementary Table S6).
Table 2 shows the top five hits identified by IPA following zinc supplementation (p-value < 0.05).
By focusing on the top canonical pathways, we were able to identify 70 pathways after apical and
48 pathways after basal zinc supplementation (−log(p-value) < 1.3, Supplementary Table S6). There
were 28 common pathways after apical and basal zinc supplementation (Supplementary Table S6).
Ostensibly unrelated canonical pathways can be interconnected through shared molecules
represented by gene names. Here we determined the network of overlapping canonical pathways
that shared at least three genes for both apical (Figure 3A) and basal (Figure 3B) supplementation
(Supplementary Table S7). In Figure 3, each canonical pathway is shown as a single “node” (the brighter
red, the more significant the pathway).
Figure 3. Overlapping canonical pathways upon zinc apical (A) or basal (B) supplementation. Each
pathway is a single “node” colored according to significance (the brighter red, the more significant
the pathway). Blue lines connect any two pathways which have at least three dataset molecules in
common. GROUP #1: adhesion to polarity; GROUP #2: protein export/import; GROUP #3: extracellular
matrix organization, GROUP #4: protein processing, GROUP #5: oxidative stress response, GROUP #6:
embryonic cell development, GROUP #7: immune response, and GROUP #8: lipid metabolism.
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Table 1. The top five hits of DAVID analysis in response to zinc supplementation.
Zinc Apical Supplementation Zinc Basal Supplementation
Category/Term Count p-Value Benjamini–Hochberg Term Count p-Value Benjamini–Hochberg
Biological process Biological process
GO:0030049~muscle
filament sliding 12 0 0.003
GO:0030198~extracellular
matrix organization 14 0 0.0735
GO:0051603~proteolysis
involved in cellular protein
catabolic process
13 0 0.0027 GO:0030334~regulation ofcell migration 9 0 0.0386
GO:0001501~skeletal
system development 21 0 0.0075
GO:0033627~cell adhesion
mediated by integrin 5 0.0001 0.0617
GO:0030198~extracellular













Cellular component Cellular component
GO:0070062~extracellular
exosome 232 0 0
GO:0070062~extracellular
exosome 120 0 0
GO:0031012~extracellular
matrix 48 0 0
GO:0031012~extracellular
matrix 29 0 0
GO:0005615~extracellular
space 119 0 0
GO:0005615~extracellular
space 60 0 0
GO:0005925~focal adhesion 49 0 0 GO:0005925~focaladhesion 28 0 0
GO:0005578~proteinaceous
extracellular matrix 38 0 0
GO:0043209~myelin
sheath 17 0 0
Molecular function Molecular function
GO:0003779~actin binding 33 0 0.0021 GO:0005178~integrinbinding 11 0 0.0075
GO:0005509~calcium ion
binding 61 0 0.0034
GO:0001948~glycoprotein
binding 8 0.0001 0.0326
GO:0001948~glycoprotein
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Table 1. Cont.
Zinc Apical Supplementation Zinc Basal Supplementation
Category/Term Count p-Value Benjamini–Hochberg Term Count p-Value Benjamini–Hochberg
GO:0005200~structural
constituent of cytoskeleton 16 0.0002 0.04
GO:0004298~threonine-type
endopeptidase activity 5 0.0004 0.051
GO:0008083~growth factor
activity 20 0.0002 0.036
GO:0051015~actin
filament binding 10 0.0005 0.0499
INTERPRO domain INTERPRO domain
IPR013098:Immunoglobulin
I-set 25 0 0
IPR001781:Zinc finger,








8 0 0.0086 IPR003096:Smooth muscleprotein/calponin 4 0.0006 0.1373
IPR024079:Metallopeptidase,






subunit alpha/beta 7 0.0001 0.0401
IPR024079:Metallopeptidase,
catalytic domain 7 0.002 0.2475
KEGG_PATHWAY KEGG_PATHWAY
hsa04978:Mineral





hsa04145:Phagosome 20 0.0004 0.0526 hsa04145:Phagosome 11 0.0012 0.1044
hsa04350:TGF-beta
signaling pathway 12 0.0053 0.3585
hsa04978:Mineral
absorption 6 0.0022 0.1251
hsa03050:Proteasome 8 0.0086 0.4214 hsa05410:Hypertrophiccardiomyopathy (HCM) 7 0.0058 0.2364
hsa04670:Leukocyte
transendothelial migration 14 0.0089 0.3623
hsa05414:Dilated
cardiomyopathy 7 0.0083 0.2655
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Table 2. The top five hits of IPA analysis in response to zinc supplementation.
Zinc Apical Supplementation Zinc Basal Supplementation
Canonical Pathways p-value Overlap Canonical Pathways p-value Overlap
ILK Signaling 6.00 × 107 13.5% 25/185 Huntington’s Disease Signaling 4.48 × 106 6.4% 15/234
Axonal Guidance Signaling 1.80 × 106 9.4% 44/467 Unfolded Protein Response 2.27 × 105 12.7% 7/55
Hepatic Fibrosis/Hepatic
Stellate Cell Activation 5.33 × 10
6 12.6% 23/182 Epithelial Adherens JunctionSignaling 1.28 × 10
4 6.7% 10/150
Epithelial Adherens Junction
Signaling 5.33 × 10
6 13.3% 20/150 Antigen Presentation Pathway 2.97 × 104 13.2% 5/38
Actin Cytoskeleton Signaling 2.38 × 105 11.3% 24/213 Protein Ubiquitination Pathway 3.25 × 104 4.9% 13/268
Upstream Regulators p-value Predicted activation Upstream Regulators p-value Predicted Activation
IgG 1.17 × 108 MRTFB 5.96 × 107
FSH 1.06 × 106 TP63 1.88 × 106
MRTFB 3.47 × 106 Activated FSH 2.66 × 106
TEAD1 3.65 × 106 TEAD2 2.39 × 105
TEAD4 3.65 × 106 TEAD3 2.79 × 105
Diseases and Disorders p-value range # Molecules Diseases and Disorders p-value range # Molecules
Neurological Disease 7.89 × 104–4.57 × 1018 315 Endocrine System Disorders 6.67 × 104–1.30 × 1011 235
Cancer 7.89 × 104–4.69 × 1015 862
Organismal Injury and
Abnormalities 7.23 × 10
4–1.30 × 1011 312
Organismal Injury and
Abnormalities 7.89 × 10
4–4.69 × 1015 873 Hereditary Disorder 7.23 × 104–1.58 × 1010 95
Gastrointestinal Disease 7.70 × 104–9.48 × 1014 774 Neurological Disease 6.61 × 104–1.58 × 1010 102
Cardiovascular Disease 6.50 × 104–3.14 × 1013 203
Skeletal and Muscular
Disorders 7.23 × 10
4–1.58 × 1010 116
Molecular and Cellular
Functions p-value range # Molecules
Molecular and Cellular
Functions p-value range # Molecules
Cellular Movement 4.19 × 104–7.88 × 1019 189 Cellular Movement 2.47 × 104–1.06 × 109 64
Molecular Transport 7.25 × 104–6.55 × 109 108 Protein Synthesis 1.31 × 106–6.82 × 108 40
Cellular Assembly and
Organization 5.34 × 10
4–3.26 × 108 105 Cellular Compromise 7.45 × 106–2.64 × 107 29
Protein Synthesis 1.12 × 105–4.12 × 107 81 Molecular Transport 5.71 × 104–2.64 × 107 44
Cell Death and Survival 6.87 × 104–9.45 × 107 132 Cell Death and Survival 4.86 × 104–3.59 × 107 58
Physiological System
Development and Function p-value range
Physiological System
Development and Function p-value range # Molecules
Cardiovascular System
Development and Function 6.97 × 10
4–2.19 × 1010 94
Cardiovascular System
Development and Function 1.58 × 10
4–1.74 × 107 42
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Table 2. Cont.
Zinc Apical Supplementation Zinc Basal Supplementation
Organismal Development 6.97 × 104–2.19 × 1010 118 Organismal Development 5.68 × 104–1.74 × 107 41
Tissue Development 6.97 × 104–4.23 × 107 132 Organ Morphology 1.20 × 104–6.53 × 107 9
Skeletal and Muscular System
Development and Function 5.80 × 10
4–4.99 × 106 31 Tissue Development 5.68 × 104–2.49 × 104 26
Tissue Morphology 1.93 × 105–1.93 × 105 12
Connective Tissue Development
and Function 5.68 × 10
4–2.84 × 104 19
Regulator Effect Networks Disease andFunctions Consistency Score Regulator Effect Networks disease and functions Consistency Score
TGFB1 Progressiveneurological disorder 0 -
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Overlapping pathways identified five distinct clusters of which there were four small clusters
(pyrimidine ribonucleotides de novo biosynthesis and interconversion; citrulline biosynthesis and
metabolism; IL-23 and Th17 activation; phosphoinositide biosynthesis, metabolism and degradation)
and one large cluster (the full list of canonical pathways are listed in Supplementary Table S7) with
several highly interconnected canonical pathways after apical zinc supplementation (Figure 3A).
Following basal zinc supplementation, we identified three separate clusters with two small
clusters (GP6 and hepatic fibrosis/hepatic stellate cell activation; super pathway of inositol phosphate
compounds; and phosphoinositide degradation) and one large cluster (the full list of canonical
pathways are listed in Supplementary Table S7) with multiple interconnected canonical pathways
(Figure 3B).
Within the large clusters, we identified eight groups after apical supplementation and five groups
after basal supplementation (groups are demarcated by black squares in Figure 3; Supplementary
Table S7). The five groups identified after basal supplementation are all present after apical
supplementation (adhesion to polarity, protein export/import, extracellular matrix organization,
protein processing and oxidative stress). Three unique groups (Groups #6, #7 and #8, embryonic cell
development, lipid metabolism and immune response) were identified after apical supplementation.
Regulator effects explain how predicted activated or inhibited upstream regulators might cause
increases or decreases in phenotypic or functional outcomes downstream (for more details, see [59]).
The regulator effects enrichment analysis in IPA predicted one directionally coherent network with
TGFB1 as potential upstream regulator effect, but only when cells were supplemented with apical zinc
(Figure 4). VIM, MMP2, CDKN1A, SERPINA1, F3 (also known as Tissue Factor), miR-145, and FAS
dataset genes were identified as TGFB1-targeted downstream master regulators. The predicted disease
mechanism was the inhibition of progressive neurological disorder (Figure 4). There was no regulator
effect enrichment identified after basal zinc application.
Figure 4. Influence of zinc supplementation culturing condition in retinal pigment epithelial cells.
Measured and predicted upstream and downstream regulatory effect. Orange lines and objects:
predicted activation; grey lines: not predicted effect; yellow lines: inconsistency with state of
downstream molecule; light red objects: measured increase; green object: measured decrease; blue
object: predicted inhibition. Note, this regulatory effect of TGFB1 was only detected upon zinc
apical supplementation.
4. Discussion
Identification of molecular pathways involved in the progression to late stages of AMD is vital to
develop new or improved intervention strategies to stop the development of irreversible visual loss.
One of the proposed intervention strategies for AMD is to modify the intake of a group of molecules
that includes zinc [60]. Based on the Rotterdam study [61], Blue Mountains Eye study [62] and AREDS
study [60], restoring zinc balance can slow the progression to end-stage AMD [5–7,63]. However,
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the molecular networks involved in this beneficial effect are not fully understood. In this work, we
identified potential key regulatory pathways through which zinc may exert its positive effects in vivo.
To study the effects of zinc supplementation, we used a human fetal primary RPE cell culture
model for AMD. This model has been shown to recapitulate aspects of early AMD including deposition
of sub-RPE material [34]. We followed protocols from these earlier studies to ensure best culturing
conditions and that sufficient zinc is available for the culture without causing cell toxicity [38,44].
While chronic exposure to elevated zinc reproduced the increased TEER and enhanced cell
pigmentation as reported earlier [38], there were significant individual differences between maximal
TEER values, levels of pigmentation and numbers of sub-RPE deposits in the primary RPE cell cultures
derived from three different donors (Figure 1). These differences are likely to reflect genetic and
phenotypic variations between individual donors from whom the cells were isolated from and may
reflect the variability among individuals in real life. These individual differences also suggest that
using precision medicine in the treatment of AMD can result in immense patient benefits.
Chronic treatment usually results in homeostatic cellular re-balancing [64] which may explain
the observed moderate fold changes in our experiments. However, the long-term supplementation is
aimed to reflect the long-term influence of zinc nutrition or supplementation used in population based
studies [5–7,63].
In our previous study, we only applied zinc apically [38]. However, in vivo zinc supplementation
would likely affect both basal and apical zinc availability. In this study, the basal elevation of zinc
was designed to mimic changes associated with altered zinc concentration in the sub-RPE space,
probably through transport from the systemic circulation via the choroidal vessels, while the apical
supplementation was designed to replicate changes in zinc concentration in the sub-retinal space,
where the photoreceptors and the interphotoreceptor matrix form an interdigitated layer with the apical
surface of the RPE.
To evaluate the complex effects of zinc supplementation, we combined the significant changes
observed in the transcriptome, proteome and secretomes of RPE after either apical or basal
supplementation and performed analysis using DAVID and IPA for pathway identification. Both
analyses revealed five main biological functions shared between apical and basal zinc supplementation:
oxidative stress response, protein processing, protein export/import, adhesion to polarity and
extracellular matrix organization (summarized with grouping of overlapping canonical pathways in
Supplementary Figure S2). Zinc is known to affect oxidative processes by modulating the expression
of metallothioneins [65,66], glutathione [67–69], and catalase [12,42], by stabilizing sulfhydryl groups
on proteins [70] and by replacing redox-active metals, such as copper and iron [71,72]. With ageing in
general and in AMD in particular, protein, lipid and mineral-rich deposits accumulate in the sub-RPE
space. The effects on protein processing and protein export/import in this study suggest that zinc
supplementation might modulate directly sub-RPE accumulation. The effects of zinc in sub-RPE deposit
formation in clinical studies are varied (see review [73,74]) and will require further investigations,
probably with the use of methods that are able to specifically identify sub-RPE deposits in a clinical
setting [75–77]. Changes in cell adhesion to polarity [78] and modulation of extracellular matrix
organization had also been reported in AMD [31,79] which highlight another layer of complexity of
zinc action on the RPE. As RPE activation and migration are significant clinical signs of the progression
of AMD [80], this finding could point to new studies in which the clinical effects of zinc could
be evaluated based on these new clinical endpoints. Overall, these findings highlight that zinc
supplementation or increased nutrient intake have diverse effects on the RPE. Given that both apical
and basal supplementation triggered these biological effects, increasing zinc concentration in the retina
or in the blood circulation appears to be beneficial in AMD.
However, there were several biological functions affected specifically following apical zinc
supplementation in our experiments. It is not yet known how the availability of zinc is regulated in
health or in disease in the subretinal space. In the photoreceptor outer segments there is a high demand
for zinc for the normal function of opsins [81–83]. This demand could be served by the release of zinc
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from the zinc-rich RPE [84], transport through the RPE from the choroid via zinc specific transport
mechanisms [85,86] or release of zinc from the Müller glia [87]. As availability of apical zinc is critical
for maintaining the high demand for the visual cycle [81–83,88–91] examining effects of increased
apical zinc further.
The biological functions affected specifically by apical zinc supplementation were embryonic cell
development, immune response and lipid metabolism. Differentiation and dedifferentiation of RPE
had been linked with AMD [92]. Zinc is a known effector of infection and immunity via NF-kappaB
activation and its targets such as TNF-alpha, IL-1beta, A20 and PPAR-alpha and inhibition of cyclic
nucleotide phosphodiesterase [71,93] and as inflammation is strongly associated with AMD [57,94–96]
our findings suggest that further clinical investigations are needed to uncover the relationship between
zinc and the immune function. In addition, disturbances in lipid metabolism, both genetically and
functionally, in AMD are well documented (for review see [97]). Therefore, these specific apical effects
observed in our study suggest potential targets of zinc supplementation that could be studied further
to identify new mediators for the progression of AMD in vivo.
We also investigated how the effect of zinc might directly link with the genes whose polymorphisms
have been independently associated with AMD [2,55,56]. From these 67 AMD-associated genes, apical
zinc supplementation influenced 6, and basal zinc supplementation affected one gene (Supplementary
Figure S3). Amongst these, we found a significantly increased expression of CFI following basal
zinc supplementation. Zinc supplementation in AMD patients has been shown to reduce the activity
of the complement system [98] and our results on CFI suggest that this reduced activity might be
due to the increased expression of CFI. Another regulator of the complement system is CFH, one
of the most significantly associated gene in relationship to AMD [2,55]. In our study, we found
inconsistent zinc induced changes in both CFH transcripts, intracellular or secreted protein levels
which might be due to low sample size and our donor to donor variability in the CFH genotype
(Supplementary Tables S1–S4). Another major AMD gene association is related to HTRA1/ARMS2,
and we found a significant increase in cellular HTRA1 protein levels, although there was no significant
change observed in the transcriptome or apical or basal secretomes (Supplementary Tables S2–S4).
Whether the significant cellular change is related to the fact that all three donors were homozygous
for the low-risk ARMS2 rs10490924 and HTRA1 rs11200638 genotype needs further examination on
larger samples sizes. The direct clinical implications of zinc supplementation regarding these genes are
highlighted in the recent controversy regarding the role of zinc in AMD progression in the AREDS
study. Awh et al. [99] reported that patients with two CFH risk alleles and no ARMS2 alleles progressed
more frequently to late AMD when supplemented with zinc, while those with no or just one CFH
risk allele and one or two ARMS2 risk alleles did benefit from zinc supplementation. These results,
however, could not be replicated by Chew et al. [100]. Together with our data, further examination of
zinc and genotype/protein activity might be highly relevant for AMD patients.
Regulator effects analysis in IPA enables generation of a hypothesis for how a phenotype, function
or disease is regulated in a dataset by activated or inhibited upstream regulators. While there were
no regulator effects predicted for basal zinc supplementation, apical zinc supplementation identified
TGFB as a predicted master regulator (Figure 4). There is an emerging role for TGFB signaling in
AMD [101,102] partly due to its role in angiogenesis [103]. Interestingly, its role in AMD is likely to
be related to its receptor (TGFBR1) in RPE rather than the TGFB itself [101,102]. TGFB secreted by
choroidal macrophages [102] seems to elicit secretion of VEGF by RPE leading to changes in vascular
behavior [102]. While TGFB was expressed in our model, confirming a previous report [104], its
levels were not modulated by changing zinc. However, downstream targets for TGFB, such as VIM
(vimentin), MMP2, CDKN1A, SERPINA1, miR-145, F3 (tissue factor) and FAS, were all modulated
by apical zinc supplementation (Figure 4). Vimentin directly interact with zinc and this interaction
affects its assembly as well as redox sensing [105]. Due to its association with epithelial-mesenchymal
transition, pigmentary abnormalities as well as the migration of RPE, vimentin also plays a role in
the pathogenesis of AMD [106,107]. MMPs and their inhibitors play a role in the pathogenesis of
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AMD [108] [109,110] by reorganizing the extracellular matrix [111] and reduction in the build up of
sub-RPE material [58]. CDKN1A is involved in RPE differentiation, proliferation, migration, and
cell-cycle progression [112]. As such, CDKN1A plays a role in the ageing process of RPE and hence
in AMD [113]. SERPINA1 is serine protease inhibitor and has a role in prevention against tissue
destruction [114]. This protein was reported as a component of drusen [115] and its level in vitreous is
directly associated with neovascular AMD and linked to increased immune response [116]. miR-145
is a biomarker for early detection of congenital hemochromatosis in AMD [117] and neovascular
AMD [118]. miR-145 downregulates junctional cell adhesion molecules and actin-bundling proteins,
resulting in a reduction in cell motility [119]. Tissue factor (F3) has been significantly upregulated in
human macular lesions in AMD, initiating intracellular signaling and promoting inflammation and
angiogenesis [120,121]. Finally, FAS-mediated apoptosis has been shown to be involved in AMD [122]
via mediating RPE survival under oxidative stress conditions [123]. Therefore, it is possible that zinc
might replace/substitute TGFB in eliciting a positive response in AMD.
5. Conclusions
In summary, we found that zinc supplementation has the potential to directly influence a number
of molecular pathways. In a multi-factorial disease such as AMD, these wide-ranging effects are
probably not surprising. The finding that zinc could act as a potential master regulator similar to that
of TGFB1 might help to explain the benefit observed in clinical studies. Studies with a larger sample
size and cells directly derived from AMD patients might help to refine our observations.
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